Journey Medical (DERM)
(Delayed Data from NSDQ)
$5.47 USD
+0.01 (0.18%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $5.47 0.00 (0.00%) 6:46 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
DERM 5.47 +0.01(0.18%)
Will DERM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DERM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DERM
4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last?
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates
DERM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA
Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards?
Other News for DERM
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors
Buy Rating on Journey Medical Corp: DFD-29 Poised to Capture Rosacea Market with Strong Revenue and Patent Position
Journey Medical resumed with a Buy at Roth MKM
Journey Medical Corp Shareholders Back Key Proposals